The global Bispecific Antibody Market size was valued at USD x billion in 2021, growing at a CAGR of x% during the forecast period 2022-2028. Gowing to launch of new products in the market in the future years. For instance, there are more than 200 bispecific antibodies products in the clinical trials which will be launched mostly among them in the future years. Increasing investments in research and development of the development of bispecific antibody market products and rising prevalence of cancer. According to WHO, around 9.6 people across the globe are responsible for death due to cancer. Presently only two drugs are approved by the U.S.FDA catumaxomab and blinatumomab. Around 30 bispecific antibodies are expected to be launched in the upcoming years that increases the growth of the market. However, limited number of products available in the market and lack of awareness among the patient population restrains the growth of the market. A bispecific antibody is a synthetic protein made up of fragments from two distinct monoclonal antibodies that can bind to two different types of antigens. The most well-studied application of bispecific antibodies is cancer immunotherapy. The majority of bispecific antibodies are being created to treat various malignancies, with infectious disease, CNS diseases, inflammatory, and autoimmune disorders following closely behind. Bispecific antibodies have a higher binding avidity to targets, can interact with more than one surface antigen, and have more cytotoxic effects than monoclonal therapies.